Fractional BD Intelligence — Senior-Level Scouting Without the Full-Time Overhead

SECTION 1: THE PROBLEM WE SOLVE

Most seed-to-Series A biotechs face the same paradox:

You have a compelling asset. You need partners, funders, and co-development conversations. But a full-time BD hire costs $200K+ per year — before benefits, equity, and the 6–12 months it takes to onboard and produce results.

OniX Hub was built for exactly this gap.

 

We deliver fractional BD intelligence — meaning you get senior-level research, outreach, and warm introductions on a scoped monthly engagement, starting when you need it and scaling as your pipeline grows.

​

SECTION 2: THE REAL DIFFERENTIATOR — ACCESS

It's Not Just Intelligence. It's Access.

Any firm can pull a researcher list. What OniX delivers is something most BD consultants simply cannot replicate: direct, trusted access built over 25+ years on every side of the funding and partnership equation.

Three layers of access that come with every OniX engagement:

🔬 Academic & Innovation Access 1,000+ direct relationships across universities, biotech parks, and research institutions in 20+ countries — built through tenures at JDRF (managing a $650M global research portfolio) and PCORI (founding team member of a $4B congressionally mandated research institution).

💰 Funding Organization Access A verified network of 500+ funding organizations spanning:

• Federal agencies: NIH, NSF, ARPA-H, DoD, BARDA, CIHR, UKRI, FNRA, NHMRC, JSPS

• Private foundations and disease-specific nonprofits

• Venture capital and pharma-dedicated VC funds

• A growing family office network with active life sciences mandates

🤝 The Last Mile OniX doesn't just deliver names. We make direct, trusted outreach on your behalf — pre-qualifying interest, gauging IP availability, and handing you warm introductions to researchers and partners who are already engaged and expecting to hear from you.

That's the difference between a spreadsheet and a conversation that leads somewhere.

​

SECTION 3: THE ONIX AI DISCOVERY ENGINE

Four Agents. One Platform. Built Specifically for Life Sciences BD.

OniX's intelligence is powered by a proprietary four-agent AI platform that monitors the global research and funding landscape continuously — so you always know what's emerging, what's fundable, and who's ready to talk.

Agent 1 — Global Foundation & Tech Transfer Scout Monitors 500+ funding sources (NIH, CIHR, UKRI, JSPS, ERC, AMED, and more) and institutional technology transfer offices (TTOs) worldwide. Harvests early-stage grant funding and IP disclosures to identify academic assets ready for licensing or partnership — before they reach the open market.

Agent 2 — Scientific Maturity & Evidence Integration Agent Validates asset strength by triangulating three independent data streams:

• PubMed / literature (mechanistic consensus and scientific credibility)

• ClinicalTrials.gov, EU Clinical Trials Information System (CTIS), Health Canada's Clinical Trials Database, ISRCTN Registry, Japan Registry of Clinical Trials (jRCT) (validation status and competitive trial landscape)

• Patent databases (freedom-to-operate and commercial defensibility)

Generates a Translational Readiness Score to determine when a discovery is truly partnership-ready — and when it isn't.

Agent 3 — Regulatory & Translational Impact Agent Maps the path to market. Synthesizes FDA regulatory guidance, CMS coverage policy, and evolving global health standards to assess how a specific mechanism will navigate the regulatory and reimbursement landscape toward commercial authorization.

Agent 4 — Dynamic Capital & Funding Intelligence Scout High-frequency monitoring of thousands of active funding opportunities — federal agencies, private foundations, venture capital, pharma-dedicated VC funds, and a growing network of family offices with life sciences mandates. Matches your pipeline's profile to active RFPs, open calls, and strategic capital mandates in real time.

​

SECTION 4: WHAT ONIX DOES FOR YOUR COMPANY

What a Fractional BD Engagement Actually Delivers

Depending on your pipeline and stage, an OniX engagement can include any combination of:

✓ Precision scouting of academic and industry partners aligned to your asset(s) ✓ Warm introductions to researchers and potential co-development partners — not cold emails ✓ Non-dilutive funding identification (NIH, NSF, ARPA-H, SBIR/STTR, foundations) to extend runway and de-risk assets ✓ Connection to VC, pharma VC, and family office capital networks actively deploying in your therapeutic area ✓ Competitive landscape mapping for your lead indication(s) ✓ Regulatory and reimbursement pathway assessment ✓ Monitoring of emerging global assets that could complement, compete with, or be in-licensed into your portfolio ✓ Federal co-funding partnership structuring — where OniX helps leverage your seed investment into NIH/NSF/ARPA-H matching dollars

​

All delivered on a scoped, monthly retainer — no long-term contracts, no full-time overhead.

​

SECTION 5: WHO THIS IS FOR

Is OniX Right for You?

Fractional BD engagements are designed for:

• Seed to Series A biotechs with 1–3 assets and an active pipeline

• Academic spinouts preparing for their first industry partnership or licensing conversation

• Rare disease companies needing global scouting across low-prevalence indications

• Platform technology companies seeking to identify the right disease indication and development partner simultaneously

• International biotechs entering the US market and needing NIH/federal funding navigation alongside BD support

 

If you have a compelling asset but not yet the BD infrastructure to surface the right partners and funders — OniX was built for you.

​

SECTION 6: PROOF OF CONCEPT

See What OniX Produces

OniX has completed precision scouting engagements across multiple therapeutic areas:

• Rare Bone Disease — 44 emerging researchers mapped across 15 countries, 8+ therapeutic modalities classified, 9+ funding bodies tracked simultaneously

• Hidradenitis Suppurativa — 20 researchers across 9 countries, competitive landscape and BD-ready profiles delivered

• FOP (Fibrodysplasia Ossificans Progressiva) — Active ACVR1 researcher landscape including confirmed NIH grant numbers, ClinicalTrials.gov-verified active trial PIs, and gene therapy partnership candidates

 

[See Full Case Studies →] → /case-studies

 

We are happy to run a brief scouting snapshot for one of your own indications — no commitment required. [Request a Sample →]

​

SECTION 7: HOW TO GET STARTED

Three Simple Steps

1. Book a 20-Minute Strategy Call Tell us about your pipeline, your stage, and your most pressing BD or funding need. No pitch deck required.

2. We Scope a Pilot Engagement Based on your priorities, we define the indication(s), geographies, and output format — and get started within 1–2 weeks.

3. You Receive Intelligence + Introductions Monthly deliverables, weekly status updates, and direct access to Martin throughout the engagement.

​​

[Read OniX OnPoint on Substack →] → https://onixonpoint.substack.com/